CRF Connect Logo

Structural

Aortic Valve Intervention Learning Series

Clinical Trials & Science

Advertisement

Structural >
Clinical Trials & Science

Episodes

Outcomes of Patients With New Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry
Outcomes of Patients With New Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry
18 min.
Atrioventricular Conduction System Changes During Transcatheter Aortic Valve Replacement (TAVR): Anatomic and Electrophysiologic Predictors of Heart Block in Prospective 400 Patient EPS/TAVR Study
Atrioventricular Conduction System Changes During Transcatheter Aortic Valve Replacement (TAVR): Anatomic and Electrophysiologic Predictors of Heart Block in Prospective 400 Patient EPS/TAVR Study
22 min.
Trancatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)
Trancatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)
21 min.
Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Study Cohort
Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Study Cohort
10 min.
Cardiac Output, Cerebral Blood Flow and Cognitive Functioning in Patients Undergoing Transcatheter Aortic Valve Implantation
Cardiac Output, Cerebral Blood Flow and Cognitive Functioning in Patients Undergoing Transcatheter Aortic Valve Implantation
9 min.
Prophylactic Antithrombotic Therapy After TAVR
Prophylactic Antithrombotic Therapy After TAVR
12 min.
Pharmacotherapy to Slow AS Progression and Protect the Heart
Pharmacotherapy to Slow AS Progression and Protect the Heart
9 min.
EARLY TAVR
EARLY TAVR
5 min.
EVOLVED: CMR As an Early Marker of Risk
EVOLVED: CMR As an Early Marker of Risk
6 min.
Moderate AS With Heart Failure: TAVR UNLOAD
Moderate AS With Heart Failure: TAVR UNLOAD
4 min.
Moderate AS With Cardiac Damage: The PROGRESS Trial
Moderate AS With Cardiac Damage: The PROGRESS Trial
5 min.
Moderate AS With Cardiac Damage: The EXPAND TAVR II Trial
Moderate AS With Cardiac Damage: The EXPAND TAVR II Trial
8 min.
TAVR vs SAVR in Low Gradient AS: Evidence Updates
TAVR vs SAVR in Low Gradient AS: Evidence Updates
18 min.
Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial
Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial
17 min.
Importance of Patient Reported Outcomes
Importance of Patient Reported Outcomes
14 min.
An Echo Deep Dive of the PARTNER  5-Year Study
An Echo Deep Dive of the PARTNER 5-Year Study
13 min.
Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY
Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY
18 min.
Perspectives on Mortality in the PARNTER 5-Year Study
Perspectives on Mortality in the PARNTER 5-Year Study
15 min.
ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation
ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation
16 min.
Four-Year Outcomes From the EVOLUT Low Risk Trial
Four-Year Outcomes From the EVOLUT Low Risk Trial
19 min.
Five-Year Clinical and Echocardiographic Outcomes From The PARTNER 3 Low-Risk Randomized Trial
Five-Year Clinical and Echocardiographic Outcomes From The PARTNER 3 Low-Risk Randomized Trial
23 min.
Comparison of Two Self-Expanding Transcatheter Heart Valves for Degenerated Surgical Bioprostheses: The AVENGER Multi-Center Registry
Comparison of Two Self-Expanding Transcatheter Heart Valves for Degenerated Surgical Bioprostheses: The AVENGER Multi-Center Registry
12 min.
Moderate AS With Heart Failure: UNLOAD and Beyond
Moderate AS With Heart Failure: UNLOAD and Beyond
9 min.
Prognostic Value of Tricuspid Valve Gradient After Transcatheter Edge-To-Edge Repair: Insights from the TriValve Registry
Prognostic Value of Tricuspid Valve Gradient After Transcatheter Edge-To-Edge Repair: Insights from the TriValve Registry
9 min.
SPOTLIGHT LECTURE: Failed TAVR Management -Lessons Learned From Registry Experiences
SPOTLIGHT LECTURE: Failed TAVR Management -Lessons Learned From Registry Experiences
14 min.
Clinical Data for the ACURATE Platform
Clinical Data for the ACURATE Platform
16 min.
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
14 min.
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
Update From the Clinical Trials and Where I Would and Wouldn’t Use It
15 min.
Progress in Self-Expanding TAVR: OPTIMIZE PRO and the Evolut Fx
Progress in Self-Expanding TAVR: OPTIMIZE PRO and the Evolut Fx
17 min.
Progress in Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial
Progress in Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial
8 min.
Pharmacotherapy to Prevent Calcific Aortic Stenosis: Novel Targets and Novel Study Methodologies
Pharmacotherapy to Prevent Calcific Aortic Stenosis: Novel Targets and Novel Study Methodologies
9 min.
How Do We Communicate Known vs Uncertain Risks and Benefits of TAVR to Younger (<65 yo) Patients?
How Do We Communicate Known vs Uncertain Risks and Benefits of TAVR to Younger (<65 yo) Patients?
14 min.
SPOTLIGHT LECTURE Staging of Aortic Stenosis According to Cardiac Dysfunction: Recent Updates
SPOTLIGHT LECTURE Staging of Aortic Stenosis According to Cardiac Dysfunction: Recent Updates
17 min.
Using CMR Imaging to Identify High-Risk Severe AS Patients (Introduction to the EVOLVED Study)
Using CMR Imaging to Identify High-Risk Severe AS Patients (Introduction to the EVOLVED Study)
5 min.
Sensor-Guided TAVR Initial experience with the SavvyWire: Post-Market Registry of the First 60 Cases
Sensor-Guided TAVR Initial experience with the SavvyWire: Post-Market Registry of the First 60 Cases
7 min.
Safety and Efficacy of Cerebral Embolic Protection Systems in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis
Safety and Efficacy of Cerebral Embolic Protection Systems in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis
18 min.
SPOTLIGHT INNOVATION LECTURE: The CEP Paradox: Reconciling Clinical Evidence, Patient’s Expectations and Future Technological Developments
SPOTLIGHT INNOVATION LECTURE: The CEP Paradox: Reconciling Clinical Evidence, Patient’s Expectations and Future Technological Developments
8 min.
ShortCut Dedicated Aortic Leaflet Splitting Device: Clinical Experience and Emerging Indications
ShortCut Dedicated Aortic Leaflet Splitting Device: Clinical Experience and Emerging Indications
14 min.
Can Scoring the Calcified Aortic Valve Defer the Need for Permanent Implant (Leaflex): Technology and Clinical Update
Can Scoring the Calcified Aortic Valve Defer the Need for Permanent Implant (Leaflex): Technology and Clinical Update
12 min.
Aortic Valve Lithotripsy Before TAVR: Early Human Clinical Experience
Aortic Valve Lithotripsy Before TAVR: Early Human Clinical Experience
6 min.
TAVR Explant: What Every Interventionalist (and Surgeon) Needs to Know
TAVR Explant: What Every Interventionalist (and Surgeon) Needs to Know
8 min.
Bioprosthetic Valve Failure and Durability—Does TAVR Really Outperform SAVR?
Bioprosthetic Valve Failure and Durability—Does TAVR Really Outperform SAVR?
8 min.
Surgical ADVANCEMENTS in Aortic Valve Regurgitation: When to… Repair vs. Ross vs. Replace with Root Management?
Surgical ADVANCEMENTS in Aortic Valve Regurgitation: When to… Repair vs. Ross vs. Replace with Root Management?
10 min.
Intersection of Guidelines and Clinical practice : Meaningful Guardrails Provide a Necessary Framework
Intersection of Guidelines and Clinical practice : Meaningful Guardrails Provide a Necessary Framework
7 min.
Update on the Evidence – Registries are Enough
Update on the Evidence – Registries are Enough
6 min.
Optimal Anti-Thrombotic Therapy After TAVR – Updates and Controversies
Optimal Anti-Thrombotic Therapy After TAVR – Updates and Controversies
10 min.